Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



3 Reasons This Top Dividend Stock Might Be a Value Trap

The wisdom of investing in large, stable companies that pay an attractive dividend has stood the test of time. That said, not all dividends -- or large companies, for that matter -- are created equal.

British pharma giant GlaxoSmithKline (NYSE: GSK  ) , for example, appears to be an exception to this time-tested investing strategy. The company pays a dividend of 4.7% at current levels, making it one of the highest among health care stocks. Moreover, analysts seem to expect fairly steady growth in adjusted earnings per share over the next several years. Viewed this way, Glaxo looks like a stellar long-term buy.

That being said, there are three compelling reasons the company looks to me more like a classic value trap.

Reason No. 1 
In April, Teva Pharmaceutical  (NYSE: TEVA  )  launched a generic version of Glaxo's former blockbuster Omega 3 pill Lovaza. Glaxo reported that first-quarter sales of the drug had already dropped 25% in anticipation of the launch of the cheaper generic. 

While Glaxo certainly has other drugs in its arsenal, I am unconvinced the company can compensate for this substantial revenue loss and grow earnings in the manner expected by the Street. In fact, projected earnings growth is expected to come mainly from cost savings via an ongoing reorganization. 

Keeping with this idea, the market uptake of Glaxo's new asthma therapy Breo Ellipta has been slower than expected due to insurance issues, putting more pressure on the company's other new respiratory medicines like Anoro and Incruse to generate top line growth. And when we dig into this restructuring process a bit further, I think it raises the next major question mark hanging over the company.

Reason No. 2
In something of a surprising move, Glaxo recently traded its high-margin oncology unit for Novartis'  (NYSE: NVS  )  less profitable vaccine business. Although it's true that this move bolsters one of Glaxo's core areas of expertise, oncology is among the fastest-growing segments within the pharmaceutical industry because these drugs often have long commercial lifespans and high profit margins. 

The thinking on the Street is that Glaxo decided to exit oncology because of its string of high-profile clinical failures. Backing up this assertion, Glaxo made this announcement less than a month after its lung cancer vaccine MAGE-A3 failed in a second late-stage trial.

What's important to understand is that MAGE-A3 was once believed to be a potential blockbuster that would go on to become one of Glaxo's top oncology treatments. So it's certainly possible that these clinical setbacks drove the decision to drop oncology and focus on vaccines That said, I think the lack of a dedicated oncology unit will end up hurting Glaxo's long-term growth.

Reason No. 3
And then there's the mess in China that seems to be getting worse by the day. Glaxo ran into trouble last year when a 10-month probe turned into allegations that top-level managers were bribing doctors and hospitals. At first, it appeared that the scandal only involved Chinese managers, but authorities have since charged the company's British boss in China, Mark Reilly, with bribery as well. 

It's unclear if this scandal will ultimately impact Glaxo's fundamentals or outlook moving ahead. My guess is that fines will be levied against the company, but the bigger impact might be slower growth in emerging markets due to tighter regulations. Given that emerging markets were the one bright spot in the first quarter for pharma sales, this certainly could become a keystone issue down the road. 

Foolish wrap-up
Despite falling U.S. sales for pharmaceuticals and vaccines in the first quarter of this year, Glaxo's stock shrugged off the larger downturn in the health-care sector, churning higher by 5.3% year to date. Part of this strong performance is undoubtedly due to growing EPS stemming from the company's restructuring. Nonetheless, you have to consider how falling sales for a handful of established products, the company's exit from the cancer market, and self-imposed marketing restrictions in some emerging markets could affect top line growth moving forward. Given these question marks, investors might want to exercise caution with this top health-care name, despite its better than average dividend.  

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 23, 2014, at 9:07 PM, Ravi786 wrote:

    This is the first article that pointed out the importance of profit margin and how the gsk shake up affects its long term prospects. Lack of oncology unit drives out r&d talent out of the company as well. Gsk gave away gold to novartis and bought copper. Dump GSK.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2964079, ~/Articles/ArticleHandler.aspx, 8/28/2015 11:24:59 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

George Budwell

George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.

Today's Market

updated Moments ago Sponsored by:
DOW 16,607.20 -47.57 -0.29%
S&P 500 1,986.33 -1.33 -0.07%
NASD 4,812.76 0.06 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 11:08 AM
GSK $40.92 Down -0.29 -0.71%
GlaxoSmithKline CAPS Rating: ****
NVS $98.00 Down -0.64 -0.65%
Novartis CAPS Rating: ****
TEVA $65.27 Up +0.07 +0.11%
Teva Pharmaceutica… CAPS Rating: ****